Apheresis Market Size (2024 - 2029)

Apheresis Market Analysis

The Apheresis Market size is estimated at USD 3.52 billion in 2024, and is expected to reach USD 4.62 billion by 2029, growing at a CAGR of 5.63% during the forecast period (2024-2029).

The COVID-19 pandemic had a profound impact on the growth of the Apheresis Market, due to the extensive application of plasma therapy to treat patients infected with COVID-19. According to the study published in the Journal of Clinical Apheresis in December 2021, the lack of supplies, notably RBC units and Apheresis kits, was one of the main problems with patient treatment in the Apheresis Facilities during the COVID-19 pandemic. Due to "stay home" instructions and concern about SARS CoV2 infection, the number of blood donors drastically reduced. Thus, the studied market was initially impacted by the pandemic. Moreover, there were no vaccines or drugs to treat COVID-19, and most doctors opted for convalescent plasma therapy, utilizing Blood Processing Technology, in patients who were severely affected by COVID-19. In this treatment, the plasma extracted from the blood of cured patients by the Plasmapheresis technique was transfused into the patient who underwent treatment. Thus, given the wide usage of Apheresis Devices in treating COVID-19 patients and increasing product approvals by the United States Food and Drug Administration (FDA), the Apheresis Market marked a positive growth during the pandemic; however, currently as the pandemic subsided, the market lost some traction, however it is expected to have a stable growth during the forecast period of the study.

The propelling factors for the growth of the Global Apheresis Market include the increasing burden of diseases, a rise in the demand for blood components and their associated safety, technological advancements in the development of new Apheresis Equipment and Cell Separation Technology, and an increase in the reimbursement policies and funding for Apheresis Services. For instance, in June 2022, through the NHS MedTech Funding Mandate (MTFM), NHS England in the United Kingdom has chosen the automated red blood cell exchange (RBCX) treatment carried out on the business's Spectra Optia Apheresis System to treat sickle cell disease. Due to this choice, Spectra Optia will be used more frequently in hospitals all around England. Patients with sickle cell illness will now have better access to this therapy. Thus, the increasing funding initiatives related to Apheresis are propelling the market growth.

The use of Therapeutic Apheresis in clinically ill patients is increasing day by day, and it has been widely used as the primary therapy or as an adjunct to other treatments for various diseases, such as thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, drug toxicities, autoimmune disease, sepsis, and fulminant hepatic failure.

Along with these factors, the increasing product innovations and approvals have been driving the Apheresis Equipment Market growth. For instance, in July 2021, Terumo Blood and Cell Technologies announced a direct offering for physicians to perform extracorporeal photopheresis immunotherapy (ECP) procedures at the patient's bedside. The company has expanded the functionality of Spectra Optia. The UVA PIT System ECP can now be performed using these devices as a functionally closed, online, multistep system with mononuclear cell collection (MNC) and continuous mononuclear cell collection (CMNC) protocols. Thus, owing to the aforementioned factors, the Apheresis Devices Market is expected to witness healthy growth over the forecast period. However, lack of skilled professionals, blood contamination, and cost associated with Apheresis Procedures restrain the market growth.

Apheresis Industry Segmentation

As per the scope of the report, apheresis is a medical technique where the blood of an individual, either a donor or a patient, is passed through an apparatus that segregates out a particular constituent and returns the rest to the blood circulation. It involves blood purification and blood component separation using centrifugation or membrane filtration technology. This procedure is performed for the blood donation component or the treatment of disease. The apheresis market is segmented by product (devices and disposables), apheresis procedure (leukapheresis, plasmapheresis, plateletpheresis, erythrocytapheresis, and other apheresis procedures), technology (centrifugation and membrane separation), application (renal disorders, hematological disorders, neurological disorders, autoimmune disorders, and other applications), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.